DELPOR INC
San Francisco, CA · Founded 2009 · CIK 0001494224 · Medtech · Private
Subcutaneous passive implant reservoir delivering tizanidine for spasticity treatment over 4+ months
delpor.com →- Grants
- $16M
- 13 awards
- Sector median: 1
- Raised
- $1.4M
- 2 Form D · Oct 2013
- 156 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 38
- 10 granted · 28 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20092011201320152017201920212023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $900,492 | |
| Private capital raised | Form D · SEC | $470,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Risperidone Subcutaneous Implant | $1,057,986 | |
| Federal grant | Department of Health and Human Services · Phase I · Sustained 3-Month Delivery of Olanzapine for Schizophrenia Maintenance Treatment | $224,389 | |
| Federal grant | Department of Health and Human Services · Phase I · Sustained Month Delivery of Olanzapine for Schizophrenia Maintenance Treatment | $224,389 | |
| Federal grant | Department of Health and Human Services · Phase II · Sustained 3-Month Delivery of Stabilized Exenatide Through Nanopore Membranes for Type 2 Diabetes Therapy | $741,023 | |
| Federal grant | Department of Health and Human Services · Phase II · Sustained 3-Month Delivery of Stabilized Exenatide Through Nanopore Membranes for Type 2 Diabetes Therapy | $1,475,430 | |
| Federal grant | Department of Health and Human Services · Phase II · Sustained 3-Month Delivery of Stabilized Exenatide Through Nanopore Membranes for Type 2 Diabetes Therapy | $734,407 | |
| Federal grant | Department of Health and Human Services · Phase I · Sustained 3-Month Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity | $224,798 | |
| Federal grant | Department of Health and Human Services · Phase I · Sustained 3-Month Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity | $224,798 | |
| Federal grant | Department of Health and Human Services · Phase II · Risperidone Subcutaneous Implant | $4,037,027 | |
| Federal grant | Department of Health and Human Services · Phase II · Risperidone Subcutaneous Implant | $2,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Sustained Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity | $1,280,691 | |
| Federal grant | Department of Health and Human Services · Phase II · Sustained Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity | $2,527,179 | |
| Federal grant | Department of Health and Human Services · Phase II · Sustained Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity | $1,246,488 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1451 | CELLOGY, INC. | — | — |
| 1452 | SOSTOS LLC | — | — |
| 1453 | Cradle Genomics, Inc. | — | — |
| 1454 | DELPOR INC | — | $1.4M |
| 1455 | Daedalus Medical Solutions, Inc. | — | $380K |
| 1456 | ACES Diagnostics, Inc. | — | $1.9M |
| 1457 | Dash Bio, Inc. | — | $17M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Nicolaos ArvanitidisDirector
- Douglas CrawfordDirector
- Ernest MarioDirector
- Francis MartinDirector · Executive Officer
- Anastassios NicolaouDirector · Executive Officer
- Anastassios NicolauDirector · Executive Officer
- Carl SpetzlerExecutive Officer
Patents
- Implantable Devices For The Sustained Delivery Of An Opioid Antagonist And Methods For Treating Inflammatory, Neuroinflammatory And Metabolic Disordersapplication
- Compositions For Small Molecule Therapeutic Agent Compoundsapplication
- Stable Compositions For Incretin Mimetic Compoundsapplication
- Compositions Of Opioid Antagonists, Implant Devices, And Treatment Methods For Opioid Use Disorderapplication
- Compositions For Small Molecule Therapeutic Agent Compoundsapplication
- Method Of Treating Schizophrenia With An Implantable Device For Long-term Delivery Of Drugsapplication
- Implantable Device For Long-term Delivery Of Drugsgranted
- Compositions For Small Molecule Therapeutic Agent Compoundsapplication
- Implantable Device For Long-term Delivery Of Drugsgranted
- Compositions For Small Molecule Therapeutic Agent Compoundsapplication
- Stable Compositions For Incretin Mimetic Compoundsapplication
- Device And Method For Sustained Release Of Antipsychotic Medicationsgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.